WHO ICTRP trial
N15DOP: Phase I and pharmacological study of weekly ModraDoc006/r in combination…
NL-OMON55802 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55802 |
|---|---|
| Public title | N15DOP: Phase I and pharmacological study of weekly ModraDoc006/r in combination with high-dose intensity-modulated radiation therapy in patients with high-risk early stage prostate cancer |
| Scientific title | N15DOP: Phase I and pharmacological study of weekly ModraDoc006/r in combination with high-dose intensity-modulated radiation therapy in patients with high-risk early stage prostate cancer - N15DOP: Oral Docetaxel/ritonavir with RT in high risk prostate cancer |
| Primary sponsor | Antoni van Leeuwenhoek Ziekenhuis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Prostate cancer;10038364;Prostate cancer |
| Interventions | Addition of treatment with ModraDoc006/ritonavir to the standard treatment with radiotherapy and hormonal therapy. ;Oral Docetaxel;Prostate cancer;Radiotherapy |
| Registration date | May 12, 2021 |
| Target size | 35 |
| Secondary IDs | 2015-004272-30 ;NL55216.031.15 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: